$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000117887922000014 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$81.69M	$80.73M	$78.72M
YoY Change	2.7%	4.29%	18.54%
Cost Of Revenue	$13.44M	$8.197M	$7.582M
YoY Change	14.88%	-2.18%	15.95%
Gross Profit	$68.26M	$72.53M	$71.13M
YoY Change	0.6%	5.07%	18.83%
Gross Profit Margin	83.55%	89.85%	90.37%
Selling, General & Admin	$47.27M	$53.38M	$58.12M
YoY Change	2.53%	26.26%	24.38%
% of Gross Profit	69.26%	73.59%	81.7%
Research & Development	$52.97M	$78.32M	$81.52M
YoY Change	-10.72%	24.31%	27.14%
% of Gross Profit	77.61%	107.98%	114.6%
Depreciation & Amortization	$1.286M	$1.334M	$1.411M
YoY Change	-15.39%	-14.87%	-12.03%
% of Gross Profit	1.88%	1.84%	1.98%
Operating Expenses	$102.1M	$133.1M	$146.5M
YoY Change	-7.4%	23.44%	29.72%
Operating Profit	-$33.84M	-$60.61M	-$75.34M
YoY Change	-20.19%	56.08%	42.0%
Interest Expense	$9.620M	$8.257M	$8.147M
YoY Change	17.82%	1.31%	1.94%
% of Operating Profit
Other Income/Expense, Net	$13.63M	$7.268M	$1.902M
YoY Change	5652.74%	3005.98%	-159.44%
Pretax Income	-$29.26M	-$61.25M	-$81.45M
YoY Change	-42.03%	31.15%	27.1%
Income Tax	$4.023M	$911.0K	$3.809M
% Of Pretax Income
Net Earnings	-$33.29M	-$62.16M	-$85.26M
YoY Change	-33.82%	21.34%	29.84%
Net Earnings / Revenue	-40.75%	-76.99%	-108.31%
Basic Earnings Per Share	-$0.12	-$0.21	-$0.30
Diluted Earnings Per Share	-$0.12	-$0.21	-$0.30
COMMON SHARES
Basic Shares Outstanding	280.5M shares	292.0M shares	288.5M shares
Diluted Shares Outstanding	289.2M shares	292.0M shares	288.5M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$354.7M	$386.8M	$411.2M
YoY Change	-36.31%	0.98%	-1.49%
Cash & Equivalents	$277.6M	$235.6M	$233.3M
Short-Term Investments	$77.11M	$151.2M	$177.9M
Other Short-Term Assets	$38.26M	$37.37M	$30.96M
YoY Change	90.55%	54.56%	42.67%
Inventory	$13.27M	$20.88M	$24.32M
Prepaid Expenses
Receivables	$52.30M	$52.56M	$52.42M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$458.5M	$497.6M	$518.9M
YoY Change	-29.51%	3.57%	3.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$32.45M	$33.66M	$34.54M
YoY Change	-22.72%	-20.55%	-20.49%
Goodwill	$197.8M	$197.8M	$197.8M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$23.00M	$23.00M	$23.00M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$17.87M	$18.05M	$25.19M
YoY Change	-19.05%	-14.88%	22.64%
Total Long-Term Assets	$301.0M	$302.9M	$308.0M
YoY Change	-1.68%	-1.12%	0.29%
TOTAL ASSETS
Total Short-Term Assets	$458.5M	$497.6M	$518.9M
Total Long-Term Assets	$301.0M	$302.9M	$308.0M
Total Assets	$759.5M	$800.6M	$826.9M
YoY Change	-20.61%	1.74%	2.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.05M	$23.11M	$22.91M
YoY Change	-50.78%	67.95%	42.23%
Accrued Expenses	$132.8M	$122.2M	$87.63M
YoY Change	66.74%	55.86%	37.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$164.7M	$164.6M	$129.7M
YoY Change	35.96%	47.0%	30.15%
LONG-TERM LIABILITIES
Long-Term Debt	$391.3M	$390.7M	$390.0M
YoY Change	0.67%	0.06%	0.05%
Other Long-Term Liabilities	$8.146M	$8.207M	$7.335M
YoY Change	19.39%	25.59%	17.02%
Total Long-Term Liabilities	$8.146M	$8.207M	$7.335M
YoY Change	19.39%	25.59%	17.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$164.7M	$164.6M	$129.7M
Total Long-Term Liabilities	$8.146M	$8.207M	$7.335M
Total Liabilities	$627.0M	$627.2M	$588.3M
YoY Change	8.09%	9.46%	5.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.500B	-$2.400B	-$2.400B
YoY Change	13.64%	9.09%	14.29%
Common Stock	$2.648B	$2.634B	$2.621B
YoY Change	2.53%	11.27%	11.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$132.6M	$173.4M	$238.6M
YoY Change
Total Liabilities & Shareholders Equity	$759.5M	$800.6M	$826.9M
YoY Change	-20.61%	1.74%	2.09%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$33.29M	-$62.16M	-$85.26M
YoY Change	-33.82%	21.34%	29.84%
Depreciation, Depletion And Amortization	$1.286M	$1.334M	$1.411M
YoY Change	-15.39%	-14.87%	-12.03%
Cash From Operating Activities	-$11.63M	-$15.86M	-$58.32M
YoY Change	-50.95%	-55.85%	-19.4%
INVESTING ACTIVITIES
Capital Expenditures	$137.0K	-$355.0K	$871.0K
YoY Change	-115.39%	-2.47%	0.35%
Acquisitions
YoY Change
Other Investing Activities	$74.38M	$26.65M	$59.08M
YoY Change	109.74%	2.17%	-32.42%
Cash From Investing Activities	$74.52M	$26.29M	$58.21M
YoY Change	115.54%	2.27%	-32.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-559.0K	693.0K	-$8.154M
YoY Change	-100.28%	-68.98%	-192.35%
NET CHANGE
Cash From Operating Activities	-11.63M	-15.86M	-$58.32M
Cash From Investing Activities	74.52M	26.29M	$58.21M
Cash From Financing Activities	-559.0K	693.0K	-$8.154M
Net Change In Cash	62.33M	11.12M	-$11.63M
YoY Change	-70.6%	-239.3%	-153.15%
FREE CASH FLOW
Cash From Operating Activities	-$11.63M	-$15.86M	-$58.32M
Capital Expenditures	$137.0K	-$355.0K	$871.0K
Free Cash Flow	-$11.76M	-$15.51M	-$59.19M
YoY Change	-48.43%	-56.4%	-19.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33497
	dei	Entity Registrant Name EntityRegistrantName	Amicus Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0869350
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3675 Market Street,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Philadelphia,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19104
	dei	City Area Code CityAreaCode	(215)
	dei	Local Phone Number LocalPhoneNumber	921-7600
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	FOLD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	280498461	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235639000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	245197000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	151202000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	237299000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	52556000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	52672000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	20879000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	26818000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	37367000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34848000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	497643000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	596834000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30447000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20586000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22188000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19882000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33657000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42496000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	197797000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	197797000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18045000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24427000	usd
CY2022Q2	us-gaap	Assets Assets	800589000	usd
CY2021Q4	us-gaap	Assets Assets	905140000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	23113000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21513000	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	114703000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	98153000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	19266000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	18900000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7543000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7409000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	164625000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	145975000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	390652000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	389357000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52844000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43363000	usd
CY2022Q2	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	5906000	usd
CY2021Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	5906000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4930000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4930000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8207000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8240000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	627164000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	597771000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	280456667	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	280456667	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	278912800	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	278912800	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2811000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2808000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2631110000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2595419000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-16603000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	5251000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-637000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-270000	usd
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	83000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	83000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2443339000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2295922000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	173425000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	307369000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	800589000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	905140000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	80731000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77413000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	159446000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	143815000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8197000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8380000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15779000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14919000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	72534000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	69033000	usd
	us-gaap	Gross Profit GrossProfit	143667000	usd
	us-gaap	Gross Profit GrossProfit	128896000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	78319000	usd
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	63003000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	159836000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	127120000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53379000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42276000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	111495000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89002000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-115000	usd
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1021000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1073000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1492000	usd
CY2022Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6616000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1334000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1567000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2745000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3171000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	133147000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	107867000	usd
	us-gaap	Operating Expenses OperatingExpenses	279619000	usd
	us-gaap	Operating Expenses OperatingExpenses	220785000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-60613000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-38834000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-135952000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-91889000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	356000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	50000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	489000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	215000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	8257000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	8150000	usd
	us-gaap	Interest Expense InterestExpense	16404000	usd
	us-gaap	Interest Expense InterestExpense	16142000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7268000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	234000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9170000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2966000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61246000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46700000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142697000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110782000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	911000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4525000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4720000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6107000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-62157000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-51225000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-147417000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-116889000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-367000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	291970562	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	291970562	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	266398516	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	266398516	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288646587	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288646587	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	265384865	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	265384865	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-62157000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-51225000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-147417000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-116889000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-16183000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	235000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-21854000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	843000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-29000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-367000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-16212000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	247000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22221000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	855000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78369000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50978000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-169638000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-116034000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	238617000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	999000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	285000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12463000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-29000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-16183000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-62157000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	173425000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	307369000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1858000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9278000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43114000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-21854000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-147417000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	173425000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	250896000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2500000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	244000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11736000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	235000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-51225000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	213910000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	286380000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6661000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	14438000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32090000	usd
	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	19230000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	21000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	843000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-116889000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	213910000	usd
	us-gaap	Profit Loss ProfitLoss	-147417000	usd
	us-gaap	Profit Loss ProfitLoss	-116889000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1295000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2745000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3171000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	43114000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	32090000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1073000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1492000	usd
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-353000	usd
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-3235000	usd
	fold	Asset Impairment Charges And Other Asset Write Offs AssetImpairmentChargesAndOtherAssetWriteOffs	12265000	usd
	fold	Asset Impairment Charges And Other Asset Write Offs AssetImpairmentChargesAndOtherAssetWriteOffs	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4424000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3127000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3537000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4445000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4481000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5265000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	22671000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-28485000	usd
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-2762000	usd
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-1784000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74177000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108277000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	184061000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	258767000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	98330000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	145255000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1226000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1234000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	84505000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	112278000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	41000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	389000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	19230000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9278000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14438000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1858000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6661000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7461000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11064000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-12462000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1439000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9595000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13626000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	249456000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166162000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	239861000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179788000	usd
	us-gaap	Interest Paid Net InterestPaidNet	15108000	usd
	us-gaap	Interest Paid Net InterestPaidNet	15109000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	710000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4526000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	191000	usd
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	usd
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	67000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2400000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>. The Company's accounts receivable at June 30, 2022 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6600000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	80731000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77413000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	159446000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	143815000	usd
CY2022Q2	us-gaap	Contractual Obligation ContractualObligation	20000000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235600000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235639000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	235639000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	387281000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	441000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	386841000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235639000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	235639000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	151642000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	441000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	151202000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	387281000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	441000	usd
CY2022Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	386841000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	245197000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	245197000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	482568000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	79000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	482496000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	245197000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	245197000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	237371000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	79000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	237299000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	482568000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	79000	usd
CY2021Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	482496000	usd
CY2021	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	140500000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	173400000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235639000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176538000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	4222000	usd
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3250000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	239861000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179788000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11508000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12289000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5943000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10699000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3428000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3830000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	20879000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	26818000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1100000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1100000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	390652000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	389357000	usd
CY2022Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7589000	usd
CY2021Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7604000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	15089000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	15125000	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	375000	usd
CY2021Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	383000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	739000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	720000	usd
CY2022Q2	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	283000	usd
CY2021Q2	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	262000	usd
	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	556000	usd
	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	485000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14731000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5402000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.55
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	339000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	333000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	178000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.98
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19283000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	22200000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17589000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.18
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	21500000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10377000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.38
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	18300000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12463000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11736000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43114000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32090000	usd
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	156163000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19266000	usd
CY2022Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4977000	usd
CY2022Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	24243000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	242048000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20339000	usd
CY2021Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4800000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	25139000	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19151000	usd
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	26296000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20339000	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25825000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-115000	usd
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1021000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1073000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1492000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19266000	usd
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27317000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19266000	usd
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27317000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-62157000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-51225000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-147417000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-116889000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	291970562	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	291970562	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	266398516	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	266398516	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288646587	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288646587	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	265384865	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	265384865	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29449000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22832000	shares

Files In Submission

Name	View Source	Status
0001178879-22-000014-index-headers.html	Edgar Link	pending
0001178879-22-000014-index.html	Edgar Link	pending
0001178879-22-000014.txt	Edgar Link	pending
0001178879-22-000014-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-06302022xex311.htm	Edgar Link	pending
fold-06302022xex312.htm	Edgar Link	pending
fold-06302022xex321.htm	Edgar Link	pending
fold-20220630.htm	Edgar Link	pending
fold-20220630.xsd	Edgar Link	pending
fold-20220630_cal.xml	Edgar Link	unprocessable
fold-20220630_def.xml	Edgar Link	unprocessable
fold-20220630_htm.xml	Edgar Link	completed
fold-20220630_lab.xml	Edgar Link	unprocessable
fold-20220630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2022 Q3 Form 10-Q Financial Statement

#000117887922000014 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2022 Q3 Form 10-Q Financial Statement

#000117887922000014 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold